ENTA vs LBRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LBRX Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LB Pharmaceuticals Inc Common Stock (LBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ENTA counters with relative strength in Valuation. Fundamentally, ENTA trades at 44.0x Forward P/E with -90.0% operating margin (-21.6% YoY revenue) versus LBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against LBRX sits in CONSOLIDATION (12th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTA | LBRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $326.2M | $1.4B | Larger Scale | LBRX |
| Trailing P/E Ratio Valuation | 44.0x | N/M | Lower Multiple | ENTA |
| Forward P/E Ratio Valuation | 44.0x | N/M | Lower Multiple | ENTA |
| Revenue Growth (YoY) Growth | -21.6% | +0.0% | Higher Growth | LBRX |
| Operating Margin (TTM) Profitability | -90.0% | 0.0% | Higher Margin | LBRX |
| Net Profit Margin Profitability | -96.9% | 0.0% | Higher Margin | LBRX |
| Return on Equity (ROE) Capital Efficiency | -70.1% | -38.8% | Higher ROE | LBRX |
| 52-Week Range Position Momentum | 10% ($10โ$17) | 80% ($14โ$50) | Stronger Trend | LBRX |
| Beta / 30D Volatility Risk Regime | 0.89ฮฒ ยท 58% Vol | 1.04ฮฒ ยท 62% Vol | Lower Realized Risk | ENTA |
| Unified Institutional Score Composite Signal | 46.2 / 100 (HOLD) | 35.5 / 100 (SELL) | Higher Composite | ENTA |